Clinical trials provide allow researchers to gain valuable knowledge and insight in their work towards finding a cure for cancer. At Johnston Health, we are proud to be a part of that mission. Through a agreement with Duke Cancer Network, Johnston Health is able to provide clinical research studies. Clinical trial submissions include, but are not limited to: new studies, amendments, renewals, safety letters, Investigator Drug Brochures (IDBs), advertisements, study tools, and Data and Safety Monitoring Board (DSMB) reports.
We follow strict protocol to ensure that all clinical trials protect the rights, privacy, and confidentiality of all subjects. Johnston Health’s Research Review Committee assures the consent process and informed consent are appropriate for the subject population, and our Local Research Review Committee will confirm that all requirements of the proposed research are met.
Site specific studies available through Johnston Health are as follows:
Randomized Phase III Trial of Adjuvant Therapy comparing Chemotherapy Alone without Trastuzumab to Chemotherapy Plus Trastuzumab.
CTSU SWOG S1007
Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in patients with 1-3 positive Nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
Phase III Trial of 6 versus 12 treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage 3 Colon Cancer.
Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Bencitabine, Cisplatin, and Placebo in Pts with Advanced Transitional Cell Carcinoma.
Sunitnib as maintenance therapy, stg IIIB/IV NSCLC prev tx with combo tx (Advanced).
Phase III Double blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced NSCL Cancer.
Prognostic validation of the BMI, airflow obstruction, dyspnea, and exercise capacity (BODE index) in Inoperable NSCLC (Advanced).
Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients.
PROLONG OMB CELL
Phase III, Open Label, Randomized, Multicenter trial of Ofatumumab Maintenance Treatment versus no further Treatment in subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) who have Responded to Induction Therapy.